Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Urolithiasis
Published in: Urolithiasis 5/2021

01-10-2021 | Urolithiasis | Original Paper

LITHOSCREEN: a comprehensive screening program and database for the assessment and treatment management of patients with kidney stones

Author: William G. Robertson

Published in: Urolithiasis | Issue 5/2021

Login to get access

Abstract

The aim of the LITHOSCREEN project was to construct a comprehensive screening program and database for recording and assessing the various risk factors for stone-formation in patients with urolithiasis. It is intended for use in Stone Clinics and is now being made available free of charge to researchers in the field who wish to maintain a comprehensive record of their patients’ medical histories, demographic backgrounds, lifestyle activities, metabolic abnormalities, biochemical risk of forming stones of various types, diet histories, stone analysis and long-term treatment records. From the recorded data for each patient, the program automatically calculates numerous functions important in the understanding of the clinical and chemical risk factors for stone-formation, including the renal handling of the ions involved, various metabolic functions, the biochemical risk of forming kidney stones (PSF), the Tiselius Indices of the supersaturation of urine with respect to calcium oxalate and calcium phosphate, the projected effects of changing the composition of each patient’s urinary composition on the risk of stone recurrence, and a program for analysing the diet of patients. It automatically produces one-page Summaries of each patient’s biochemical and dietary records with abnormal values highlighted according to a “traffic-light” colour-coding system and generates charts designed to improve patient compliance with treatment in the form of colour-coded “Target Diagrams” showing (a) the patient’s 24-h urine composition, (b) the patient's biochemical risk of forming stones of different types and (c) the composition of the patient’s diet. The Summary pages and “Target Diagrams” are suitable for inclusion in the patient’s Case Notes. LITHOSCREEN also produces charts projecting the effect of changing the composition of urine on the patient's biochemical risk of forming further stones. These graphs provide clues as to which urinary risk factors to target to reduce the patient’s risk of stone recurrence.
Literature
1.
Robertson WG (1982) Urolithiasis: epidemiology and pathogenesis. In: Husain I (ed) Tropical urology and renal disease. Churchill Livingstone, Edinburgh, pp 143–164
2.
Smith LH (1989) The medical aspects of urolithiasis: an overview. J Urol 141(3 Pt 2):707–710CrossRef
3.
4.
Robertson WG, Peacock M, Nordin BEC (1968) Activity products in stone-forming and non-stone-forming urine. Clin Sci 34:579–594PubMed
5.
Tiselius H-G (1989) Standardized estimate of the ion activity product of calcium oxalate in urine from renal stone formers. Eur Urol 16:48–50CrossRef
6.
Kok DJ, Papapoulos SE (1993) Physicochemical considerations in the development and prevention of calcium. Bone Miner 20:1–15CrossRef
7.
Kavanagh JP (2006) Supersaturation and renal precipitation: the key to stone formation? Urol Res 34:81–85CrossRef
8.
Fleisch H, Bisaz S (1962) Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203:671–675CrossRef
9.
Coe FL, Parks JH (1990) Defenses of an unstable compromise: crystallization inhibitors and the kidney’s role in mineral regulation. Kidney Int 38:625–631CrossRef
10.
Shiraga H, Min W, Van Dusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426–430CrossRef
11.
Ryall RL (1997) Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 15:155–164CrossRef
12.
Cifuentes Delatte L, Minon-Cifuentes J, Medina JA (1985) Papillary stones: calcified renal tubules in Randall’s plaques. J Urol 133:490–494CrossRef
13.
Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin Loops of Henle. J Clin Invest 111:607–616CrossRef
14.
Khan SR (2011) Crystal/cell interaction and nephrolithiasis. Arch Ital Urol Androl 83:1–5PubMed
15.
Robertson WG (2017) Do “inhibitors of crystallization” play any role in the prevention of kidney stones? A critique. Urolithiasis 45:43–56CrossRef
16.
Robertson WG (2004) The scientific basis of urinary stone-formation. In: Mundy AR, Fitzpatrick JM, Neal DE, George NJR (eds) Scientific basis of urology, 2nd edn. Taylor and Francis, London & New York, pp 205–227
17.
Robertson WG, Peacock M, Nordin BEC (1969) Calcium crystalluria in recurrent renal stone-formers. Lancet 2:21–24CrossRef
18.
Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BEC (1976) Saturation-inhibitor index as a measure of the risk of calcium oxalate stone-formation in the urinary tract. N Engl J Med 294:249–252CrossRef
19.
Robertson WG (2015) Potential role of fluctuations in the composition of renal tubular fluid through the nephron in the initiation of Randall’s Plugs and calcium oxalate crystalluria in a computer model of renal function. Urolithiasis 43(Suppl 1):S93–S107CrossRef
20.
Robertson WG (1969) Measurement of ionized calcium in biological fluids. Clin Chim Acta 24:149–157CrossRef
21.
Werness PG, Brown CM, Smith LH, Finlayson B (1985) EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol 134:1242–1244CrossRef
22.
Brown CM, Ackermann DK, Purich DL (1994) EQUIL93: a tool for experimental and clinical urolithiasis. Urol Res 22:119–126CrossRef
23.
Ashby RA, Byrne JP, Györy AZ (1999) Urine is a saturated equilibrium and not a metastable supersaturated solution: evidence from crystalluria and the general composition of calcium salt and uric acid calculi. Urol Res 27:297–305CrossRef
24.
May PM, Murray K (1991) JESS, a joint expert speciation system – 1. Raison d’être. Talanta 38:1409–1417PubMed
25.
Marangella M, Petrarulo M, Vitale C, Daniele P, Sammartano S (2021) LITHORISK.COM: the novel version of a software for calculating and visualizing the risk of renal stone. Urolithiasis 49:211–217
26.
Tiselius H-G, Larsson L (1981) Biochemical evaluation of patients with urolithiasis. Europ Urol 7:31–34CrossRef
27.
Tiselius H-G (1984) A simplified estimate of the ion-activity product of calcium phosphate in urine. Europ Urol 10:91–195CrossRef
28.
Robertson WG, Tiselius H-G, Rodgers AL Comparison of various indices of urinary supersaturation and biochemical risk of stone-formation (in preparation)
29.
Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB (1978) Risk factors in calcium stone disease of the urinary tract. Br J Urol 50:449–454CrossRef
30.
Robertson WG (2003) A risk factor model of stone-formation. Frontiers Biosci 8:1330–1338CrossRef
31.
Dauw CA, Alruwaily AF, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS Jr, Hollingsworth JM (2015) Provider variation in the quality of metabolic stone management. J Urol 193:885–890CrossRef
32.
Kok DJ (2012) Metaphylaxis, diet and lifestyle in stone disease. Arab J Urol 10:240–249CrossRef
33.
Pearle MS, Goldfarb DS, Assimos DG et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324CrossRef
34.
Robertson WG (2012) General and specific dietary advice for the prevention of stone recurrence. In: Talati JJ, Tiselius H-G, Albala DM, Ye Z (eds) Urolithiasis–basic science and clinical practice. Springer, London, pp 709–720
35.
Robertson WG (2012) Methods for diagnosing the risk factors of stone-formation. Arab J Urol 10:250–257CrossRef
36.
Wu W, Yang B, Ou L, Liang Y, Wan S, Li S, Zeng G (2014) Urinary stone analysis on 12,846 patients: a report from a single center in China. Urolithiasis 42:39–43CrossRef
37.
Remer T, Manz F (1995) Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc 95:791–797CrossRef
38.
Robertson WG, Peacock M, Heyburn PJ, Hanes FA (1980) Epidemiological risk factors in calcium stone disease. Scand J Urol Nephrol 53(Suppl):15–28
39.
Ӧner M, Koutsoukos P, Robertson WG (2021) Kidney stones formation – thermodynamic, kinetic and clinical aspects, In: Amjad Z, Demadis K eds. Water-Formed Deposits: Fundamentals and Mitigation Strategies; chapter 25. Elsevier (in press)
40.
Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH (1983) The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 130:1115–1118CrossRef
41.
Robertson WG, Peacock M (1985) The origin of metabolic abnormalities in primary calcium stone disease - natural or unnatural selection? In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W (eds) Urolithiasis and related clinical research. Plenum Press, New York, pp 287–290CrossRef
Metadata
Title
LITHOSCREEN: a comprehensive screening program and database for the assessment and treatment management of patients with kidney stones
Author
William G. Robertson
Publication date
01-10-2021
Publisher
Springer Berlin Heidelberg
Keyword
Urolithiasis
Published in
Urolithiasis / Issue 5/2021
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-021-01276-0

Other articles of this Issue 5/2021

Urolithiasis 5/2021 Go to the issue

Original Paper

Minimally invasive percutaneous nephrolithotomy with SuperPulsed Thulium-fiber laser

Original Paper

Does the duration between urine culture and percutaneous nephrolithotomy affect the rate of systemic inflammatory response syndrome postoperatively?

Original Paper

Urinary stone disease prevalence and associations in cystic fibrosis

Letter to the Editor

“Trust my morphology”, the key message from a kidney stone

Original Paper

Clinical analysis of 13 children with primary hyperoxaluria type 1

Original Paper

Urine osmolality predicts calcium-oxalate crystallization risk in patients with recurrent urolithiasis